Loading…
Piramal Pharma (PPLPHARMA)₹246.37+0.07%Pharmaceuticals
Piramal Pharma is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a ROCE of 3.0% against a peer median of 24.0%, and latest-quarter sales growth of 27.9% against a peer median of 26.0%. By market cap it is #7 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IPCA Laboratories | 49,726 | 38.0 | 17.1 | 15.7 | 0.10 | 0.3 | 9,591 | 1,186 | 20.7 | 82.0 | vs PPLPHARMA |
| GlaxoSmithKline Pharmaceuticals | 45,799 | 42.8 | 61.1 | 45.5 | 0.01 | 2.1 | 3,818 | 1,038 | 16.6 | 15.6 | vs PPLPHARMA |
| Emcure Pharmaceuticals | 42,108 | 41.5 | 24.0 | 20.0 | 0.31 | 0.2 | 9,187 | 940 | 22.8 | 35.8 | vs PPLPHARMA |
| Ajanta Pharma | 41,800 | 33.1 | 35.0 | 27.0 | 0.06 | 1.8 | 5,442 | 1,055 | 32.4 | 49.3 | vs PPLPHARMA |
| Sai Life Sciences | 38,940 | 107.0 | 20.0 | 15.4 | 0.12 | 0.0 | 2,197 | 349 | 11.6 | 21.6 | vs PPLPHARMA |
| Wockhardt | 32,910 | 81.0 | 8.0 | 6.1 | 0.45 | 0.0 | 3,364 | 199 | 26.0 | — | vs PPLPHARMA |
| Piramal Pharma | 32,767 | — | 3.0 | −3.9 | 0.70 | 0.0 | 8,842 | −327 | 27.9 | — | — |
| Acutaas Chemicals | 31,798 | 72.5 | 32.0 | 24.0 | 0.02 | 0.1 | 1,340 | 356 | 42.7 | 71.0 | vs PPLPHARMA |
| Rubicon Research | 29,334 | 100.5 | 27.9 | 27.0 | 0.24 | 0.1 | 1,758 | 248 | 51.8 | 97.4 | vs PPLPHARMA |
| Neuland Laboratories | 26,012 | 52.5 | 26.0 | 21.2 | 0.16 | 0.2 | 2,017 | 364 | 119.4 | 956.7 | vs PPLPHARMA |
| Alembic Pharmaceuticals | 20,041 | 28.9 | 13.1 | 13.5 | 0.25 | 1.2 | 7,321 | 671 | 25.6 | 11.5 | vs PPLPHARMA |
| Peer median | 32,910 | 47.7 | 24.0 | 20.0 | 0.16 | 0.2 | 3,818 | 364 | 26.0 | 49.3 |
Listed companies closest to Piramal Pharma in Pharmaceuticals include IPCA Laboratories, GlaxoSmithKline Pharmaceuticals, Emcure Pharmaceuticals, Ajanta Pharma, Sai Life Sciences, Wockhardt, Acutaas Chemicals, Rubicon Research.
IPCA Laboratories, with a market cap of ₹49,726 Cr.
Piramal Pharma's return on capital employed is 3.0%, below the peer median of 24.0%.